注册号: Registration number: |
ChiCTR2100050914 |
最近更新日期: Date of Last Refreshed on: |
2022-10-14 |
注册时间: Date of Registration: |
2021-09-08 |
注册号状态: |
预注册 |
Registration Status: |
Prospective registration |
注册题目: |
纸质和中文电子版WOMAC量表一致性和可比性测试 |
Public title: |
Consistency and comparability test of paper and Chinese electronic version of the Western Ontario and McMaster Universities (WOMAC) scale |
注册题目简写: |
|
English Acronym: |
|
研究课题的正式科学名称: |
纸质和中文电子版WOMAC量表一致性和可比性测试 |
Scientific title: |
Consistency and comparability test of paper and Chinese electronic version of WOMAC scale |
研究课题代号(代码): Study subject ID: |
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
申请注册联系人: |
张禹杰 |
研究负责人: |
元唯安 |
Applicant: |
Zhang Yujie |
Study leader: |
Yuan Wei'an |
申请注册联系人电话: Applicant telephone: |
+86 17717921308 |
研究负责人电话: Study leader's telephone: |
+86 13774269261 |
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
申请注册联系人电子邮件: Applicant E-mail: |
591496585@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
weian_1980@163.com |
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
申请注册联系人通讯地址: |
上海市浦东新区张衡路528号 |
研究负责人通讯地址: |
上海市浦东新区张衡路528号 |
Applicant address: |
528 Zhangheng Road, Pudong New District, Shanghai |
Study leader's address: |
528 Zhangheng Road, Pudong New District, Shanghai |
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
申请人所在单位: |
上海中医药大学附属曙光医院 |
||
Applicant's institution: |
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine |
是否获伦理委员会批准: |
是 |
||
Approved by ethic committee: |
Yes |
||
伦理委员会批件文号: Approved No. of ethic committee: |
2021-1053-128-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
批准本研究的伦理委员会名称: |
上海中医药大学附属曙光医院伦理委员会 |
||
Name of the ethic committee: |
IRB of Shuguang Hospital affiliated with Shanghai University of TCM |
||
伦理委员会批准日期: Date of approved by ethic committee: |
2022-01-17 | ||
伦理委员会联系人: |
马俊里 |
||
Contact Name of the ethic committee: |
Junli Ma |
||
伦理委员会联系地址: |
上海市张衡路528号 |
||
Contact Address of the ethic committee: |
528 Zhangheng Road, Pudong New District, Shanghai |
||
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
研究实施负责(组长)单位: |
上海中医药大学附属曙光医院 |
||||||||||||||||||||||
Primary sponsor: |
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine |
||||||||||||||||||||||
研究实施负责(组长)单位地址: |
上海市浦东新区张衡路528号 |
||||||||||||||||||||||
Primary sponsor's address: |
528 Zhangheng Road, Pudong New District, Shanghai |
||||||||||||||||||||||
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
经费或物资来源: |
国家重点新药创制项目(编号:2017ZX09304002);上海市卫生健康委员会临床专项研究项目(No.201940063) |
||||||||||||||||||||||
Source(s) of funding: |
National Key New Drug Creation Project (No. 2017ZX09304002); Special Clinical Research Project of Shanghai Municipal Health Commission (No. 201940063) |
||||||||||||||||||||||
研究疾病: |
膝关节骨性关节炎 |
||||||||||||||||||||||
Target disease: |
Knee osteoarthritis |
||||||||||||||||||||||
研究疾病代码: |
|
||||||||||||||||||||||
Target disease code: |
|
||||||||||||||||||||||
研究类型: |
干预性研究 |
||||||||||||||||||||||
Study type: |
Interventional study |
||||||||||||||||||||||
研究所处阶段: |
其它 | ||||||||||||||||||||||
Study phase: |
N/A |
||||||||||||||||||||||
研究目的: |
1.评估电子和纸质版本之间评估结果的可比性。 2.评估参与者对于中文电子版WOMAC量表的接受程度(患者的依从性)。 |
||||||||||||||||||||||
Objectives of Study: |
1. Assess the comparability of assessment results between the electronic and paper versions. 2. Assess the participants' acceptance of the Chinese electronic version of the WOMAC scale (patient compliance). |
||||||||||||||||||||||
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
研究设计: |
随机交叉对照 |
||||||||||||||||||||||
Study design: |
Cross-over |
||||||||||||||||||||||
纳入标准: |
1.符合中华医学会骨科学会联合手术组发布的《骨关节炎诊断与治疗指南》(2018年版)膝关节骨性关节炎诊断标准的患者; 2.年龄在40岁至70岁,包括40和70岁,男女不限; 3.KL分类≤3级; 4.拥有手机并能熟练使用该应用程序; 5.懂中文并能独立完成WOMAC问卷; 6.签署知情同意书。 |
||||||||||||||||||||||
Inclusion criteria |
1. Patients who meet the diagnostic criteria for knee osteoarthritis in the Guidelines for Diagnosis and Treatment of Osteoarthritis (2018 Edition) issued by the Orthopaedic Society of the Chinese Medical Association and the Operation Group; 2. Aged between 40 and 70 years, including 40 and 70 years old, no gender limit; 3. KL classification <= grade 3; 4. Have a mobile phone and be proficient in using the application; 5. Understand Chinese and be able to independently complete the WOMAC questionnaire; 6. Sign the informed consent. |
||||||||||||||||||||||
排除标准: |
1.急性半月板损伤,周围韧带断裂损伤,风湿性关节炎,类风湿性关节炎,膝关节周围肿瘤,结核,膝盖特发性骨坏死; 2.严重心血管,肺,肝,肾和造血系统疾病,血友病和其他出血性疾病,精神疾病,妊娠和哺乳期; 3.对塞来昔布过敏或不耐受; 4.在最近2个月内接受过其他治疗对本研究存在干扰; 5.研究者确定不适合参加本临床试验的患者。 |
||||||||||||||||||||||
Exclusion criteria: |
1. Acute meniscus injury, peripheral ligament rupture injury, rheumatoid arthritis, rheumatoid arthritis, tumor around the knee joint, tuberculosis, idiopathic osteonecrosis of the knee; 2. Severe cardiovascular, lung, liver, kidney and hematopoietic system diseases, hemophilia and other bleeding diseases, mental illness, pregnancy and lactation; 3. Allergy or intolerance to celecoxib; 4. Received other treatments in the last 2 months that interfered with this study; 5. The investigator determines that the patient is not suitable to participate in this clinical trial. |
研究实施时间: Study execute time: |
从From2022-01-17至To 2023-12-31 |
征募观察对象时间: Recruiting time: |
从From2022-10-13至To 2023-01-16 |
干预措施: Interventions: |
|
研究实施地点: Countries of recruitment and research settings: |
|
测量指标: Outcomes: |
|
采集人体标本:
Collecting sample(s)
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
性别: |
男女均可 |
Gender: |
Both |
||||||
随机方法(请说明由何人用什么方法产生随机序列): |
张禹杰医生根据样本量和分组利用spss软件产生随机序列 |
||||||||
Randomization Procedure (please state who generates the random number sequence and by what method): |
Generated randomised sequence with SPSS by Dr Yujie Zhang |
盲法: |
|
Blinding: |
|
试验完成后的统计结果(上传文件): |
|
Calculated Results after
|
|
是否共享原始数据: IPD sharing |
是Yes |
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
由主要研究者直接提供 |
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
afford by PI |
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
利用CRF和Excel保存 |
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
saving data with CRF and Excel |
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |